Xingjuan Chao Sells 31,415 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 31,415 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total transaction of $786,317.45. Following the completion of the sale, the chief executive officer directly owned 787,799 shares of the company’s stock, valued at $19,718,608.97. This trade represents a 3.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Stock Performance

CeriBell stock opened at $24.20 on Friday. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The company has a market capitalization of $928.80 million, a price-to-earnings ratio of -13.75 and a beta of 0.81. The firm’s fifty day moving average price is $19.54 and its 200 day moving average price is $19.22.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, research analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several large investors have recently modified their holdings of CBLL. Russell Investments Group Ltd. grew its stake in CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock worth $64,000 after purchasing an additional 854 shares in the last quarter. Sei Investments Co. lifted its holdings in CeriBell by 2.3% during the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after buying an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after acquiring an additional 1,393 shares during the last quarter. Finally, Strs Ohio acquired a new stake in shares of CeriBell during the 1st quarter valued at approximately $27,000.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CBLL. BTIG Research increased their price target on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Barclays raised CeriBell to a “neutral” rating in a research report on Tuesday. Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Canaccord Genuity Group raised their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.40.

Trending Headlines about CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Analyst price targets increased. BTIG Research raised its target from $28 to $30 and reiterated a Buy rating, while Canaccord Genuity lifted its target from $25 to $26 and also maintained a Buy rating. These revisions indicate continued confidence in CeriBell’s growth prospects. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional interest has been supportive. TimesSquare Capital Management initiated a position valued at approximately $15.2 million, while KCM Capital increased its holdings by 40% to 1.4 million shares. Additional firms also established or expanded positions, suggesting some professional investors see value in CBLL.
• Neutral Sentiment: Recent financial results were mixed. CeriBell’s quarterly revenue of $28.1 million exceeded the $27.28 million consensus estimate, but its $0.51 per-share loss was wider than the expected $0.47 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.96 per share.
• Neutral Sentiment: Analyst opinion remains generally favorable but valuation expectations are uneven. The consensus rating is “Moderate Buy,” although the average target of $22.40 is below the recent trading level. Barclays upgraded the stock to Neutral, reflecting a more cautious stance.
• Negative Sentiment: Senior executives sold a substantial number of shares. CEO Xingjuan Chao sold 33,614 shares for about $841,000 across August 18–19, reducing her holdings by roughly 4%. CFO Scott Blumberg sold 34,502 shares for approximately $864,000, cutting his direct ownership by about 18.45%. The transactions occurred around $25 per share, close to CeriBell’s 52-week high, and could be interpreted as profit-taking or a potential near-term confidence signal. CeriBell Insider Trading Activity

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.